ENXTPA:ALVAL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Valbiotis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALVAL is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ALVAL's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

3.4%

ALVAL

0.4%

FR Biotechs

0.4%

FR Market


1 Year Return

172.1%

ALVAL

27.7%

FR Biotechs

-3.0%

FR Market

Return vs Industry: ALVAL exceeded the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: ALVAL exceeded the French Market which returned -3% over the past year.


Shareholder returns

ALVALIndustryMarket
7 Day3.4%0.4%0.4%
30 Day2.7%7.8%13.2%
90 Day37.0%18.5%11.0%
1 Year172.1%172.1%27.8%27.7%-1.0%-3.0%
3 Year-12.7%-13.5%-35.9%-36.0%16.6%6.9%
5 Yearn/a-66.0%-66.2%44.5%24.8%

Long-Term Price Volatility Vs. Market

How volatile is Valbiotis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Valbiotis undervalued compared to its fair value and its price relative to the market?

7.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALVAL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALVAL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALVAL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: ALVAL is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALVAL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALVAL is overvalued based on its PB Ratio (7.8x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Valbiotis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-59.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALVAL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALVAL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALVAL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALVAL's revenue is expected to decline over the next 3 years (-12.5% per year).

High Growth Revenue: ALVAL's revenue is forecast to decline over the next 3 years (-12.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALVAL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Valbiotis performed over the past 5 years?

-44.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALVAL is currently unprofitable.

Growing Profit Margin: ALVAL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: ALVAL has a negative Return on Equity (-102.4%), as it is currently unprofitable.


Next Steps

Financial Health

How is Valbiotis's financial position?


Financial Position Analysis

Short Term Liabilities: ALVAL's short term assets (€12.6M) exceed its short term liabilities (€7.4M).

Long Term Liabilities: ALVAL's short term assets (€12.6M) exceed its long term liabilities (€3.6M).


Debt to Equity History and Analysis

Debt Level: ALVAL's debt to equity ratio (36.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ALVAL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ALVAL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ALVAL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.2% per year.


Next Steps

Dividend

What is Valbiotis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALVAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALVAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALVAL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALVAL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALVAL's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Sébastien Peltier (42 yo)

no data

Tenure

Mr. Sébastien Peltier, Ph.D., HDR serves as the Chief Executive Officer and Chairman of Valbiotis SA. Mr. Peltier joined Laboratoire Lescuyer in 2007 and served as its in charge of the Research & Developme...


Leadership Team

NamePositionTenureCompensationOwnership
Sébastien Peltier
Chairman & CEOno datano data9.21%
€ 4.2m
Jocelyn Pineau
CFO & Directorno datano data4.6%
€ 2.1m
Pascal Sirvent
CSO & Director2.17yrsno datano data
Murielle Cazaubiel
CMO & Director1.75yrsno datano data
Josep Infesta
Head of Global Business Development1.83yrsno datano data
Agnès Tixier
Executive Director of Credit Mutuel & Equity SCR and Member of Supervisory Board1.67yrsno datano data
Philippe Sibour
Chief Executive Officer of Alliance Consultingno datano datano data

1.8yrs

Average Tenure

Experienced Management: ALVAL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Sébastien Peltier
Chairman & CEOno datano data9.21%
€ 4.2m
Jocelyn Pineau
CFO & Directorno datano data4.6%
€ 2.1m
Pascal Sirvent
CSO & Director2.17yrsno datano data
Murielle Cazaubiel
CMO & Director1.75yrsno datano data
Agnès Tixier
Executive Director of Credit Mutuel & Equity SCR and Member of Supervisory Board1.67yrsno datano data
Laurent Lévy
Chairman of Supervisory Board3.67yrsno datano data
Nathalie Boisseau
Member of Scientific & Medical Boardno datano datano data
Jean-Marie Bard
Member of Scientific & Medical Boardno datano datano data
Samy Hadjadj
Member of Scientific & Medical Boardno datano datano data
Thierry Maugard
Member of Scientific & Medical Boardno datano datano data
Bruno Guigas
Member of Scientific & Medical Boardno datano datano data
André Marette
Member of Scientific & Medical Boardno datano datano data

2.0yrs

Average Tenure

47yo

Average Age

Experienced Board: ALVAL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.9%.


Top Shareholders

Company Information

Valbiotis SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Valbiotis SA
  • Ticker: ALVAL
  • Exchange: ENXTPA
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €45.935m
  • Shares outstanding: 7.66m
  • Website: https://valbiotis.com

Number of Employees


Location

  • Valbiotis SA
  • rue Paul Vatine
  • 12th Floor
  • Périgny
  • Auvergne
  • 17180
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALVALENXTPA (Euronext Paris)YesCommon SharesFREURJun 2017

Biography

Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:09
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.